# HSEF v5.3 review: Addiction as a Brain Disease

> Sources: 56 primary reports; claims: 60; verified: 60; unverified: 0. Verification is bounded attribution. Access: 2 partial-body and 54 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-10. No complete-paper audit or blinded calibration claimed.

> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 6 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Neural adaptations causally affect addiction-like behaviors in models; a general human loss-of-volition mechanism is not established.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Γ — Mechanistically plausible, partial system support | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** Within a prespecified human substance-use-disorder severity group, test an ethically permissible selective candidate-mediator manipulation with matched active comparator and independently varied alternative-reward support; register objective control and relapse outcomes.

**Belief versus evidence:** Overall Γ follows SC3. Specific experimental neural effects, clinical treatment responses and recovery trajectories support a biological/behavioral disorder with context-dependent control. They do not establish that persistent neuroadaptations generally remove voluntary control or make chronic relapse the necessary course.

**Best-supported rival:** Context-dependent neurobehavioral disorder. A prespecified human mediator manipulation crossed with matched alternative-reward support would test whether reversing the adaptation restores control beyond contextual reinforcement, with objective trajectory outcomes and credible controls.

## COMPETING MECHANISTIC MODELS

**Rank 1: Context-dependent neurobehavioral disorder (Γ).** Drug-induced adaptations interact with reinforcement, alternatives, severity and environment. Neural model perturbations coexist with human contingency-management response and heterogeneous recovery. No single integrated causal model explains all individuals or establishes every interaction.

**Rank 2: Persistent-neuroadaptation primacy (Γ).** Drug adaptations generally impose loss of voluntary control and chronic relapse. Targeted model interventions and clinical pharmacological benefit support important brain involvement. Human mediator necessity, general volitional incapacity and invariant chronicity are not demonstrated.

**Rank 3: Learning and alternative-reward control (Γ).** Choice depends strongly on reinforcement history and available alternatives. Randomized incentives and animal reward-choice studies change drug-related behavior. Neural adaptations and severe constrained choice remain real; reinforcement responsiveness does not mean brain independence.

**Rank 4: Vulnerability, social context and illness severity (Β).** Pre-existing vulnerability and contextual severity shape use and recovery. Natural-course and treatment-selection findings show marked heterogeneity. Observational course differences cannot isolate these causes or deny acquired neural mechanisms.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Addiction is a chronic relapsing brain disease in which drug-induced neuroadaptation causes loss of volitional control over use.

The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim.

Selection: remaining-priority list position 5 from the editorial list of 2026-10-09. No prior grade consulted; this is not independent blinded calibration.

### Evidence and causal interpretation

Rubric fit: 07-psychiatry-neuromodulation governs the human addiction mechanism. Rodent drug-seeking tasks supply real model causality but cannot cross its human functional threshold. Pharmacological and behavioral treatment effects are separated from selective mediator necessity and blinding/expectancy control.

The neural evidence is substantial within tested systems. Amygdala GAT-3 manipulation changed alcohol choice; amygdala ensemble/PKC-delta interventions reduced punished alcohol taking; optogenetic dopamine stimulation produced selected addiction-like model features. Those are causal experimental findings, not merely imaging correlations. Their subjects, induced exposures and behavioral proxies constrain the inference to human volition. [21] [38] [33]

Human brain findings include sensitization, altered dopamine measures and partial recovery with abstinence. These show plasticity rather than a single inevitably permanent lesion. Dependence and withdrawal are physiologically real but do not alone establish addiction or general incapacity for choice. [10] [12] [48] [16]

Objective human drug-use outcomes respond to pharmacological and behavioral interventions. X:BOT highlights treatment-induction barriers; randomized contingency management improves selected abstinence/retention outcomes. In the Brazilian trial, negative-sample proportions depended on whether expected or only submitted samples formed the denominator, making engagement part of the result. Incentive response does not prove the brain remained unchanged. [14] [51] [56] [54]

Natural-course studies document both remission and chronic severe outcomes. Severity selection and mortality prevent simplistic comparisons of treated and untreated people. Recent semaglutide AUD trials improve selected outcomes while leaving other endpoints null; they justify a treatment pathway, not a universal brain-mediated loss-of-volition theory. [6] [46] [49] [22] [23] [24]

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

<!-- consensus-consistency-2026-10-09 -->
### Consensus consistency validation — 9 October 2026

Scope: retrospective validation of the archived v5.3 review; the prior score was visible, so this is not blind calibration. The preregistered gradeable claim is that drug-induced neuroadaptation causes loss of volitional control and a generally chronic relapsing course. The registered subclaims remain SC1 (persistent neural adaptation), SC2 (neural contributions to compulsive seeking), and SC3 (general human loss-of-volition/chronic-course inference). Aggregation remains primary-subclaim SC3. Prior level/confidence: Γ, Moderate. Literature cutoff 2026-10-09; original-source checks conducted 2026-10-09 local (2026-10-10 UTC).

#### Raw Consensus provenance

The raw Consensus Pro/browser document is to be preserved unchanged in `consensus-browser-response.md` with thread metadata in `browser-thread.json`. This addendum does not reproduce or paraphrase that response as verified evidence. Connector search was used as a discovery lead for the human lesion-network and prospective relapse-prediction primary reports below. Reviews (including the Consensus-surfaced systematic review of neurocognitive predictors) and protocols are not counted as primary causal lines.

#### Primary-source checks

| Load-bearing claim | Primary report checked | Source-level observation | Before/after judgement |
|---|---|---|---|
| Focal human brain damage can be associated with addiction remission and nominate a circuit. | Joutsa et al., PMID 35697842; DOI 10.1038/s41591-022-01834-y; PubMed abstract/figures (`https://pubmed.ncbi.nlm.nih.gov/35697842/`); abstract/figure-caption access. | Two cohorts with smoking addiction at focal brain damage (n=67, n=62); lesion locations did not converge anatomically and voxel-based lesion-symptom mapping was not significant, but a lesion-network map identified connectivity associated with remission. Independent brain-damage cohort (n=186) provided an alcohol-risk generalization analysis; the authors describe the connection as a candidate target. This report was absent from the archived 56-source inventory and is a new source, not a replication in a general SUD population. | Supports a specific human circuit contribution and modestly strengthens SC2/biological involvement. It does not test drug-induced neuroadaptation, normal variation in volition, selective reversal of an addiction-associated adaptation, or a generally chronic course. No SC3 level change; confidence remains Moderate. |
| Some measured neurobehavioral markers prospectively predict relapse in a clinical sample. | MacNiven et al., PMID 37567334; DOI 10.1016/j.biopsych.2023.07.020; PubMed abstract (`https://pubmed.ncbi.nlm.nih.gov/37567334/`); abstract_metadata. | Prospective study of detoxified stimulant-use-disorder patients (n=68) and controls (n=42); 27 remained abstinent and 33 relapsed at six months. Lower anterior-insula response to monetary-loss anticipation predicted relapse, cross-validated accuracy reported as 72.7%. The response did not differ between patients and controls in the reported abstract, limiting diagnostic specificity; marker prediction is observational, not a mediator manipulation. The paper was absent from the archived inventory. | Supports bounded prediction in one stimulant cohort but not causal necessity, universal inability to choose, or a general chronic-relapse trajectory. No level/confidence change for SC3. |
| Human behavior can respond to alternative reinforcement and treatment contingencies. | Miguel et al., PMID 27442691; DOI 10.1037/adb0000192; PubMed abstract (`https://pubmed.ncbi.nlm.nih.gov/27442691/`); abstract_metadata, with archive's full_text_partial receipt retained. | In a 65-person RCT among treatment-seeking crack-cocaine-dependent participants, contingency management increased treatment attendance/retention and continuous-abstinence runs. A negative-sample proportion difference was present when all expected samples were the denominator but not when only submitted samples were used. No neural state or mediator was measured. The report is already counted in the archive as PMID27442691 and one trial. | Existing interpretation stands: objective behavior is sensitive to incentives/context, but this does not establish brain independence or absence of neuroadaptation. It counters an invariant loss-of-agency interpretation without erasing severe cases. No change. |
| A randomized contingency-management intervention can increase biologically measured alcohol abstinence; drug co-abstinence in the same factorial trial was less secure. | McDonell et al. Rewarding Recovery, PMID 33220122; DOI 10.1111/add.15349; PubMed abstract (`https://pubmed.ncbi.nlm.nih.gov/33220122/`); abstract_metadata. | 114 American Indian adults with alcohol dependence and co-use randomized in a 2×2 factorial trial. Alcohol-contingent arms increased alcohol-abstinent urine submission odds (OR 2.4–4.8); drug-abstinence contrasts were not significant in multiple-imputation analyses, and the abstract calls the drug effect inconclusive. This is one primary RCT and was not in the archived 56-source inventory. It assesses behavioral treatment contingencies, not neural state or volition. Consensus raw response markers [19.1] and [19.2] cite it. | Supports objectively measured behavioral responsiveness to an alternative contingency in this defined clinical community; it does not establish brain-independent choice or universal volitional capacity. No change to SC3 or aggregate score. |

#### Consensus-result reconciliation

Consensus surfaced the human lesion-network report as a relevant primary source; it was absent from the original evidence inventory and is added only to this audit comparison, not to the canonical review. The original source supports some brain-network involvement while remaining narrow in exposure, phenotype and causal inference. Consensus also surfaced a systematic review reporting limited evidence for neurocognition as a general addiction-outcome predictor. That is a synthesis, not an independent primary causal line; the claim was checked against a primary prospective stimulant cohort instead. The primary prospective study supports prediction in a defined sample, not mediation. The contingency-management report was already in the dossier and must not be counted twice.

Consensus also interprets incentive-driven objective outcomes as evidence of human goal-directed choice/volition. The primary RCTs demonstrate responsiveness of measured behavior under specific contingencies, not a direct measurement of volition or absence of automatic components.

The review's SC3 does not ask whether the brain matters at all. It asks whether drug-induced adaptation generally explains human loss of volitional control and a chronic relapsing course. None of these primary studies manipulates a proposed endogenous adaptation in humans while preserving the drug effect and tests objective symptom/use trajectory across a prespecified general SUD scope. The new human lesion report is meaningful support for the broad biological premise and is the strongest new counterweight; it does not satisfy the registered gate.

#### Per-subclaim score decision

- SC1 (repeated drug exposure produces persistent brain adaptations): Γ, Moderate — unchanged. The new human lesion cohort does not measure exposure-induced adaptations; archive already contains repeated experimental model and recovery evidence.
- SC2 (specific neuroadaptations contribute causally to compulsive seeking): Γ, Moderate — unchanged. Lesion-network evidence modestly reinforces brain-circuit contribution; the prospective neurobehavioral marker is predictive/associational. Neither yields human mediator necessity for general addiction.
- SC3 (drug-induced adaptations explain general human loss of volition/chronic relapsing course): Γ, Moderate — unchanged. Brain involvement and selected relapse prediction remain compatible with heterogeneous course and contextual control; neither demonstrates a necessary, general adaptation causing inability to choose.
- Aggregation remains primary-subclaim SC3; overall Γ, Moderate. No confidence-band change proposed: the new primary lesion study increases plausibility of a circuit contribution but does not close the scope/mechanism gap; the prospective association is one cohort; the pre-existing Miguel CM RCT and the new McDonell CM RCT are behavioral contingency studies, not neural-mechanism evidence. Prior level was visible; not blind calibration.

#### Source links

- PubMed primary records: https://pubmed.ncbi.nlm.nih.gov/35697842/ ; https://pubmed.ncbi.nlm.nih.gov/37567334/ ; https://pubmed.ncbi.nlm.nih.gov/27442691/
- Consensus references from connector search: Joutsa et al. paper record https://consensus.app/papers/details/a75f6a5119695a5a9a9fb4310171574a/?utm_source=unknown ; MacNiven et al. paper record https://consensus.app/papers/details/1117e86f52b65b3895a49ae1dcd9b47c/?utm_source=chatgpt



This dated supplement adds source reconciliation to the original review. Its original narrative, registered scope, source inventory and grades remain historical records. No earlier adversarial approval is attached to this case, and nothing in the record certifies this supplement. New sources described here are supplemental and are not counted in the original inventory.
<!-- end-consensus-consistency -->


### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Repeated drug exposure produces persistent brain adaptations. | Substance use disorders defined before outcome | Γ | Drug exposure changes brain signaling and structure, including persistent and reversible responses. The psychiatric rubric does not treat acute/proxy changes as positive human symptom-trajectory causality. |
| SC2 Specific neuroadaptations causally contribute to compulsive drug seeking. | Experimental models and human substance use disorders | Γ | Specific neural manipulations alter rodent drug choice, seeking and punishment resistance. Human treatments can improve outcomes but do not selectively establish the proposed adaptation as required for compulsivity. |
| SC3 Drug-induced neuroadaptation explains loss of volitional control and a generally chronic relapsing course. | Substance use disorders without outcome-selected scope | Γ | Human choice responds to incentives and alternatives, courses include remission and chronic relapse, and a universally necessary adaptation causing loss of volition is not established. This is partial mechanism support, not denial of severe addiction or biological treatment benefit. |

Preregistered aggregation: primary-subclaim. Overall Γ follows SC3. Specific experimental neural effects, clinical treatment responses and recovery trajectories support a biological/behavioral disorder with context-dependent control. They do not establish that persistent neuroadaptations generally remove voluntary control or make chronic relapse the necessary course. Sensitivities: weakest-link Γ; primary-subclaim Γ; scope-matched Γ.

### Decisive-perturbation inventory and causal tally

[1] Randomized adolescent contingency management improved marijuana abstinence during treatment. Parent training and multiple treatment components do not isolate a neural mediator or establish permanent remission.

[2] Dexamfetamine reduced cocaine-use days in refractory cocaine dependence with heroin-assisted treatment. Selected comorbidity, adverse effects and agonist substitution do not establish a universal loss-of-volition mechanism.

[5] Cellphone-linked contingency management improved alcohol-negative breath measures and selected drinking outcomes. Behavioral response does not imply no brain changes; sample submission and setting restrict scope.

[14] X:BOT found an induction hurdle for naltrexone explaining much intention-to-treat relapse difference versus buprenorphine. Per-protocol similarity conditions on successful induction; neither result proves unified loss of volition.

[15] Lorcaserin did not reduce oxycodone self-administration under tested conditions. A specific negative pharmacological test does not invalidate every neural adaptation mechanism.

[16] An opioid challenge produced withdrawal responses in morphine-stabilized dependent participants. Physiological dependence is not equivalent to addiction, compulsive choice or universal chronic relapse.

[17] Reduced-nicotine cigarettes and preferred-flavor alternatives decreased smoking in randomized high-risk groups. Nicotine exposure and alternative rewards both change; a broad neural-primacy claim is not isolated.

[18] Depot buprenorphine was noninferior on prespecified outcomes and favored the distribution of illicit-use outcomes. Active-formulation comparison supports treatment effects, not a universally necessary brain lesion.

[21] Amygdala GAT-3 knockdown shifted rats toward alcohol choice, with related human postmortem expression findings. Rat choice causality plus human association do not establish human mediator necessity or universal loss of agency.

[22] A small semaglutide AUD trial reduced laboratory consumption and selected drinking/craving endpoints. Drinks per calendar day and drinking days did not change; nonspecific intake/weight effects and small sample limit mechanism attribution.

[23] Oral semaglutide reduced selected heavy-drinking and naturalistic outcomes in AUD. Laboratory craving and drinks-per-day endpoints were not significant; drug benefit does not prove the nominal universal mechanism.

[24] Semaglutide reduced heavy-drinking days versus placebo in AUD with obesity. Obesity scope and subjective/physiological drug effects restrict mechanistic specificity and generalization.

[27] Closed-loop prefrontal inhibition altered punishment-related ethanol seeking in rats. Model circuit specificity does not prove broad human symptom-trajectory causality.

[28] N-acetylcysteine promoted punishment-linked abstinence in long-access cocaine rats and altered glutamate transport measures. Drug pleiotropy and associated molecular recovery do not isolate every causal mediator.

[31] Ventral-pallidum inhibition reduced cocaine relapse-like behavior after voluntary abstinence in rats. Model relapse and possible risk-assessment effects cannot establish universal human chronicity.

[33] Optogenetic dopamine stimulation produced reinforcement and selected relapse/compulsion-like behaviors in mice. Artificial stimulation sufficiency for a model phenotype is not endogenous necessity or universal human loss of volition.

[35] Targeted dopamine-neuron manipulations altered heroin reinforcement in mice. Reinforcement is not identical to chronic compulsivity, and species/perturbation scope matters.

[37] Corticostriatal inhibition reduced punished reward seeking in mice. Reward-proxy circuit effects do not establish human diagnostic specificity or universal agency loss.

[38] Targeted amygdala ensemble inhibition and PKC-delta knockdown reduced punishment-resistant alcohol taking in rats. Phenotype-selected animals and rodent punishment tasks do not establish a generally primary mechanism in humans.

[39] Reducing VTA histone dopaminylation changed gene expression/dopamine release and cocaine seeking in rats. A specific model relapse pathway is not a universal human brain-disease mechanism.

[41] Accumbens BRG1 inhibition and overexpression oppositely altered cocaine reinstatement in rats. Local model manipulation does not establish human necessity or the etiology of every substance disorder.

[42] GluN3A knockdown prevented incubation of cue-induced cocaine craving in rats. Cue seeking is a model phenotype, not direct human relapse or generalized volitional incapacity.

[44] VTA glutamate blockade reduced cocaine reinstatement with location and sucrose controls. Specific model reinstatement effects do not establish a human syndrome-wide causal driver.

[51] Contingent incentives improved verified smoking abstinence in opioid-maintained patients. Some duration measures were nonsignificant; reinforcement responsiveness does not imply brain-independent choice.

[52] Bupropion did not improve planned methamphetamine-use outcomes, with a post hoc light-use subgroup signal. Exploratory subgroup benefit cannot replace the primary null or invalidate all pharmacological treatment.

[53] A multisite vigabatrin trial found no protocol-defined cocaine efficacy difference. Possible medication nonadherence prevents treating the null as verified target failure.

[54] A digital therapeutic added to buprenorphine improved opioid abstinence and retention. Combined behavioral/pharmacological treatment does not identify one required neural lesion.

[55] A sequential randomized study supported selected ACT-plus-contingency-management response findings but not modafinil augmentation. Adaptive design and probabilistic evidence do not isolate a universal mediator or guarantee sustained remission.

[56] Randomized contingency management improved retention and sustained crack-cocaine-negative runs. Negative-sample proportions differed using expected samples but not submitted samples, making engagement part of the result; no neural-state measurement.

Tally: 29 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. The tally counts reports with discriminating intervention contrasts, including negative results; it is not a count of positive causal crossings. Shared parent trials and multiple manipulations within a study remain grouped.

### Cap audit, precedence and Β/Γ/Δ boundary

Rat/mouse manipulations establish model dependencies; the human psychiatric threshold retains comparator, blinding and symptom-trajectory requirements. Treatment efficacy is not proof of one specific mediator. No convergence across treatment modalities is claimed to establish the broad nominal mechanism.

Universal six-cap audit: 1: In vitro evidence alone cannot exceed Γ; cell and biochemical findings do not establish human endogenous causality. 2: Pure association evidence cannot exceed Β; association-only presence/risk/reliability subclaims retain Β. 3: Overexpression in model systems caps at Γ for the broader claim; artificially engaged targets are not endogenous human necessity. 4: Biomarker change without functional/phenotypic change caps at Γ; clocks, concentrations and immune markers cannot replace functional outcomes. 5: Seeding or forced-transfer paradigms cap at Γ for endogenous propagation claims; injected spike, transferred IgG and forced model stimulation retain their model scope. 6: Familial/syndromic genetic findings remain scope-restricted; ALS/syndromic model mechanisms do not automatically establish general aging or sporadic human disease. None of these is reapplied to downgrade a genuinely convergent same-scope causal set.

Gamma hard-rule audit: Human associations and biomarker-only changes do not establish the broad causal claim. Model perturbations bind their tested species and phenotype, not an untested human scope. Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification.

SC1 field-valid definition: “at least one of:
- Active comparator matched for acute subjective effect, blinding integrity measured and reported
- Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject
- Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia
- Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker
- Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors

Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. Drug exposure changes brain signaling and structure, including persistent and reversible responses. The psychiatric rubric does not treat acute/proxy changes as positive human symptom-trajectory causality.

SC2 field-valid definition: “at least one of:
- Active comparator matched for acute subjective effect, blinding integrity measured and reported
- Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject
- Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia
- Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker
- Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors

Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. Specific neural manipulations alter rodent drug choice, seeking and punishment resistance. Human treatments can improve outcomes but do not selectively establish the proposed adaptation as required for compulsivity.

SC3 field-valid definition: “at least one of:
- Active comparator matched for acute subjective effect, blinding integrity measured and reported
- Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject
- Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia
- Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker
- Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors

Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. Human choice responds to incentives and alternatives, courses include remission and chronic relapse, and a universally necessary adaptation causing loss of volition is not established. This is partial mechanism support, not denial of severe addiction or biological treatment benefit.

### Upward threshold ladder

SC1 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Demonstrate that the proposed persistent adaptation, not an acute pharmacodynamic marker, causally alters human symptom trajectory.

SC2 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Selectively manipulate the candidate mediator in controlled humans with credible comparator, registered functional outcomes and appropriate blinding/expectancy controls.

SC3 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. The mediator-specific intervention must predictably restore functional control/relapse trajectory within a prespecified diagnosis/severity scope, excluding alternatives without defining responders afterward.

Upper ladder: No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately.

Independence: Different publications, laboratories and agents do not automatically form independent causal lines. No nominal Ζ or higher is assigned.

### Falsification and pitfalls

Proxy phenotype. Rodent punished seeking, reinforcement and cue incubation do not directly measure human agency.

Treatment equals etiology. Medication/TMS benefit does not establish a universally necessary neural adaptation.

Unblinded comparison. The pilot TMS comparator was not a matched sham sufficient to isolate expectancy.

Recovery selection. Help-seeking severity and long-term mortality distort simplistic natural-remission comparisons.

### Adversarial steelman: above, then below

Case for Δ: selective neural manipulations alter drug choice, compulsivity and relapse-like behavior; medications and incentives improve human outcomes. These cross meaningful model/treatment thresholds, but no controlled selective human adaptation manipulation establishes the registered general loss-of-volition claim.

Case for Β: human imaging and course associations cannot determine etiology, and model tasks incompletely translate. Nevertheless, controlled neural manipulation and objective human treatment responses provide partial system support beyond correlations.

Retain Γ while recognizing causal model biology and human treatment benefit. Evidence for responsiveness is not evidence that every choice is easy or that neural mechanisms are absent.

### Final score, causal direction and M/S/D

Overall Γ follows SC3. Specific experimental neural effects, clinical treatment responses and recovery trajectories support a biological/behavioral disorder with context-dependent control. They do not establish that persistent neuroadaptations generally remove voluntary control or make chronic relapse the necessary course.

Drug exposure initiates neuroadaptations; exposure is upstream, not identical to the addiction phenotype, so step 1 does not classify every adaptation as a consequence of diagnosed addiction. Model perturbations show behavioral dependency, bypassing step 2 in that narrow scope. General human initiation plus rate limitation and universal necessity are not established (steps 3/4). The defensible mechanistic role is reinforcement/maintenance at step 5, demonstrated in models and provisional for human generalization, not a primary-driver claim.

Momentum: Mechanistic only. Targeted rodent work (PMID34407947,32273471) and recent AUD semaglutide trials (PMID42522065,42070571) test neural/treatment pathways; no verified selective human mediator trial of general volitional incapacity was identified.

Stability: Stable. No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth.

Divergence: Contested; no single implied-level arithmetic. Artifact for the split: public-health and research framing of addiction as a chronic relapsing brain disease with compromised volition implies a high rung, while the same field's randomized incentive and natural-course literature is read by other researchers as showing preserved, context-sensitive choice and frequent remission, implying a much lower one (PMID27442691,33220122,8271810). These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

Within a prespecified human substance-use-disorder severity group, test an ethically permissible selective candidate-mediator manipulation with matched active comparator and independently varied alternative-reward support; register objective control and relapse outcomes.

Readout: Verified mediator engagement, drug-negative samples, functional decision control and longitudinal relapse. Controls: Credible blinding/expectancy assessment, equal treatment scaffold, adverse-effect monitoring and objective outcome adjudication. Supporting: Mediator-specific reversal restores predicted functional control beyond comparator/context effects. Falsifying: Verified selective mediator reversal fails the registered functional predictions while contextual intervention changes outcomes.

## KNOWLEDGE GAPS

Which adaptations are necessary in humans rather than model proxies?

How much acquired versus pre-existing vulnerability explains different courses?

Recovery and chronicity vary by substance and severity.

Treatment response has not isolated a universal neural mediator.

## REVIEWER NOTES

Fifty to seventy original primary reports were selected before adjudication. Exact bounded abstract passages and selected body paragraphs are retained with examination receipts. Most papers were not read in full; absent details are limitations, not assumed controls. For the original 2026-10-09 review pass, no independent blind grading, Consensus, Scite or independent scientific peer review was performed. The dated Consensus consistency validation above is a later, separately scoped supplement: it records the Consensus discovery leads and the original-source checks made on 9 October 2026, changed no grade, and is not blind calibration either, because the prior score was visible to it. Popularity is editorial interest, not measured demand. Models are a descriptive tournament; their rankings are not independent causal proof. Grades were derived from selected primary evidence after claim registration, without consulting a previous completed grade. The primary-subclaim aggregation is fixed; weakest-link sensitivities remain displayed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## ADVERSARIAL REVIEW AND APPROVAL

Authoring model: **Sol 6.1**. Adversarial reviewer: **Claude Opus 5.5 (Anthropic)**. Date: **2026-10-14** (Round 2, group 12).
Scope of checks: 56/56 reference PMIDs verified against PubMed metadata, plus the three supplemental PMIDs introduced by the 9 October validation block (0 failed, 0 retractions or expressions of concern); 12 load-bearing claims spot-checked against abstracts, with the four source-level rows added by the revision checked line by line because a revision-introduced error matters more than an inherited one; scoring logic re-derived against `hsef-framework.md` and the v5.3 SKILL (rubric routing, pre-registered primary-subclaim aggregation, role derivation, upward ladder, M/S/D artifacts); the known upstream defects screened.

| ID | Severity | Location | Original to corrected | Basis |
|---|---|---|---|---|
| AR-1 | Major | REVIEWER NOTES, first paragraph | "No independent blind grading, Consensus, Scite or independent scientific peer review was performed." to the same sentence scoped to the original 2026-10-09 review pass, followed by a clause recording that the dated validation above is a later, separately scoped supplement that changed no grade and is not blind calibration either | Revision-introduced self-contradiction. The 9 October integration spliced in a "Consensus consistency validation" section documenting a raw Consensus Pro and browser response, connector-search discovery leads and cited Consensus markers, while leaving the preserved REVIEWER NOTES sentence denying that any Consensus work was performed. The repair scopes the original sentence rather than deleting either block, so both the original pass's limits and the supplement's provenance remain on the record. |
| AR-2 | Major | Closing paragraph of the validation block (review) and `consensus-addendum.md` | "any earlier approval remain historical records; the earlier approval does not certify this supplement" to "No earlier adversarial approval is attached to this case, and nothing in the record certifies this supplement" | Revision-introduced regression. The second clause presupposes an earlier approval even though the first hedges it. The earlier edition (`hsef_v53_remaining_priority_01_05_2026-10-09/addiction-brain-disease/`) contains no ADVERSARIAL REVIEW AND APPROVAL section and no adversarial banner, so no earlier approval exists. |
| AR-3 | Minor | "Primary-source checks" table inside the validation block | Three rows given their missing trailing cell delimiter, two blank lines removed so the fourth row rejoins the table, and a blank line inserted before the following heading | Revision-introduced rendering defect. The row added for the Rewarding Recovery trial was separated from the table by blank lines and therefore rendered as a detached, header-less one-row table, with the preceding heading absorbed. The content of all four rows is unchanged. |
| AR-4 | Minor | Score card `final_score.confidence_rationale` (3 occurrences) | "density, heterogeneous controls and incomplete access set the confidence" to a rationale stated on evidence-density and reproducibility grounds, with access explicitly excluded | Lead two-step test applied. Step 1: access depth is struck as a determinant. Step 2: the band is re-derived and stays at Moderate, because the review documents substantive evidence-quality reservations of its own — the causal results are rodent behavioural proxies, the human neural evidence is associational or predictive rather than a mediator manipulation, severity selection and mortality confound treated-versus-untreated comparisons, and course heterogeneity is marked. Those are legitimate determinants, so High is not reached. |
| AR-5 | Minor | Final score block Divergence line; score card `extended_scoring_MSD.divergence.justification` | Value unchanged at Contested; the checkable artifact naming the two conflicting framings added | Divergence is computed, not felt, and Contested requires showing that the field is genuinely split. Both prose and score card previously asserted only the absence of an arithmetic gap. The split here is unusually explicit in the literature: the chronic-relapsing-brain-disease framing against the choice and natural-recovery reading of the same incentive and course data. |
| AR-6 | Editorial | Reference 3; momentum artifact in the review and the score card | "DOI: ." to "DOI: not available."; "(PMIDs34407947,32273471)" and "(PMIDs42522065,42070571)" to the house "(PMID...)" form | Builder rendering defects. Verified that PubMed supplies no DOI for PMID 21266151, so only the empty field needed repair; the plural label was fused to the first identifier and is inconsistent with the house citation style used everywhere else in the document. |

### Rejected findings (checked, no change)

1. **Level and aggregation.** Primary-subclaim is pre-registered and applied as written: SC3 is the designated primary subclaim, it is the one that carries the website claim at its stated scope, and its Γ sets the headline while SC1 and SC2 are reported without gating. All three alternatives are reported and coincide at Γ, so no rule-shopping is possible here. Δ rejected: nothing in the corpus manipulates a proposed endogenous human adaptation while preserving the drug effect and measures an objective trajectory across a prespecified general substance-use-disorder scope, which is the registered gate. Β rejected: the amygdala GAT-3, PKCδ ensemble and optogenetic dopamine experiments are genuine causal perturbations, not correlations.
2. **Scope-matched misreading.** Checked specifically. The headline is set by the primary subclaim, and the scope-restricted model results are kept at SC2 rather than promoted to carry the general human claim.
3. **"Best-supported rival" renderer bug.** Checked and absent. The score card marks `models_evaluated[0]` as `is_nominal: false`, rank 1 (Context-dependent neurobehavioral disorder, Γ); the nominal (Persistent-neuroadaptation primacy, Γ) sits at rank 2.
4. **Momentum.** Already "Mechanistic only" and correctly so: the artifact names real work (targeted rodent studies, the 2026 alcohol-use-disorder semaglutide trials) and states that no selective human mediator trial of general volitional incapacity was identified. No change.
5. **Causal role.** `reinforcing / stabilizing factor` follows the derivation procedure, which the review walks through step by step and which lands at step 5. The prose correctly refuses `primary driver` on the ground that general human initiation, rate limitation and universal necessity are not established.
6. **The four source-level rows added by the revision.** All verified accurate against PubMed abstracts, including the figures a looser reading would round off: two smoking cohorts of 67 and 62 at focal brain damage with an independent 186-patient alcohol-risk generalization cohort and the authors' own "candidate target" framing (35697842); 68 detoxified stimulant-use-disorder patients and 42 controls with 27 abstinent and 33 relapsed at six months (37567334); the 65-person Brazilian contingency-management trial randomized 33 and 32, with the denominator distinction preserved (27442691); and 114 American Indian adults in a 2x2 factorial trial, alcohol-abstinent odds ratios of 2.4 to 4.8, drug contrasts losing significance under multiple imputation, with the abstract's own word "inconclusive" reported rather than softened (33220122). The supplemental sources are correctly excluded from the 56-source inventory, and the double-counting warning about the already-included contingency-management trial is correct.
7. **Semaglutide claims.** Checked against both 2026 trials and not overstated: the oral trial missed its primary craving endpoint and drinks per day while reducing heavy drinking days, and the once-weekly trial is confined to patients with comorbid obesity. The review's phrasing — selected outcomes improved, other endpoints null, a treatment pathway rather than a loss-of-volition theory — is accurate.
8. **Citation years.** References 4, 12, 14, 26, 27, 28, 29, 32, 43 and 54 differ from the PubMed e-pub year by one. Rejected per convention.
9. **Collective-author defect, "PMIDnot supplied", fused numeral tokens elsewhere.** Screened across all 56 references, the timeline and the evidence cards; none present beyond the two label fusions corrected in AR-6.

### Residual limitations

Only two originals were read at partial-body depth, so Methods-level detail elsewhere rests on bounded abstract and status records, as the review states; in particular the Joutsa voxel-based lesion-symptom-mapping non-significance and the MacNiven 72.7 percent cross-validated accuracy are drawn from figure captions and the abstract rather than from the full Results. The raw Consensus browser response referred to in the validation block was not available to this reviewer, so the provenance claims about it were checked only for internal consistency against the review's own statements. Access depth is unchanged (2 partial-body, 54 bounded abstract/status).

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

## REFERENCES

1. Stanger C, Budney AJ, Kamon JL et al. A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug and alcohol dependence. 2009. [PMID 19717250](https://pubmed.ncbi.nlm.nih.gov/19717250/). DOI: 10.1016/j.drugalcdep.2009.07.009. Access: abstract_metadata. Study: PMID19717250.

2. Nuijten M, Blanken P, van de Wetering B et al. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2016. [PMID 27015909](https://pubmed.ncbi.nlm.nih.gov/27015909/). DOI: 10.1016/S0140-6736(16)00205-1. Access: abstract_metadata. Study: PMID27015909.

3. García-Fernández G, Secades-Villa R, García-Rodríguez O et al. Individual characteristics and response to Contingency Management treatment for cocaine addiction. Psicothema. 2011. [PMID 21266151](https://pubmed.ncbi.nlm.nih.gov/21266151/). DOI: not available. Access: abstract_metadata. Study: PMID21266151.

4. Stitzer ML, Gukasyan N, Matheson T et al. Enhancing patient navigation with contingent financial incentives for substance use abatement in persons with HIV and substance use. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2020. [PMID 31436447](https://pubmed.ncbi.nlm.nih.gov/31436447/). DOI: 10.1037/adb0000504. Access: abstract_metadata. Study: PMID31436447.

5. Alessi SM, Petry NM. A randomized study of cellphone technology to reinforce alcohol abstinence in the natural environment. Addiction (Abingdon, England). 2013. [PMID 23279560](https://pubmed.ncbi.nlm.nih.gov/23279560/). DOI: 10.1111/add.12093. Access: abstract_metadata. Study: PMID23279560.

6. Grella CE, Stein JA. Remission from substance dependence: differences between individuals in a general population longitudinal survey who do and do not seek help. Drug and alcohol dependence. 2013. [PMID 23791039](https://pubmed.ncbi.nlm.nih.gov/23791039/). DOI: 10.1016/j.drugalcdep.2013.05.019. Access: abstract_metadata. Study: PMID23791039.

7. Orsini CA, Colon-Perez LM, Heshmati SC et al. Functional Connectivity of Chronic Cocaine Use Reveals Progressive Neuroadaptations in Neocortical, Striatal, and Limbic Networks. eNeuro. 2018. [PMID 30073194](https://pubmed.ncbi.nlm.nih.gov/30073194/). DOI: 10.1523/ENEURO.0081-18.2018. Access: abstract_metadata. Study: PMID30073194.

8. Caprioli D, Jupp B, Hong YT et al. Dissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015. [PMID 25740505](https://pubmed.ncbi.nlm.nih.gov/25740505/). DOI: 10.1523/JNEUROSCI.3890-14.2015. Access: abstract_metadata. Study: PMID25740505.

9. Franklin TR, Wang Z, Sciortino N et al. Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study. Drug and alcohol dependence. 2011. [PMID 21333466](https://pubmed.ncbi.nlm.nih.gov/21333466/). DOI: 10.1016/j.drugalcdep.2011.01.015. Access: abstract_metadata. Study: PMID21333466.

10. Boileau I, Dagher A, Leyton M et al. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Archives of general psychiatry. 2006. [PMID 17146013](https://pubmed.ncbi.nlm.nih.gov/17146013/). DOI: 10.1001/archpsyc.63.12.1386. Access: abstract_metadata. Study: PMID17146013.

11. Morimoto MM, Tanaka S, Mizutani S et al. In Vivo Observation of Structural Changes in Neocortical Catecholaminergic Projections in Response to Drugs of Abuse. eNeuro. 2018. [PMID 29445765](https://pubmed.ncbi.nlm.nih.gov/29445765/). DOI: 10.1523/ENEURO.0071-17.2018. Access: abstract_metadata. Study: PMID29445765.

12. Rademacher L, Prinz S, Winz O et al. Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers. Biological psychiatry. 2016. [PMID 26803340](https://pubmed.ncbi.nlm.nih.gov/26803340/). DOI: 10.1016/j.biopsych.2015.11.009. Access: abstract_metadata. Study: PMID26803340.

13. D'Onofrio G, Herring AA, Hawk KF et al. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. JAMA. 2026. [PMID 41670966](https://pubmed.ncbi.nlm.nih.gov/41670966/). DOI: 10.1001/jama.2025.27019. Access: abstract_metadata. Study: NCT04225598.

14. Lee JD, Nunes EV, Novo P et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet (London, England). 2018. [PMID 29150198](https://pubmed.ncbi.nlm.nih.gov/29150198/). DOI: 10.1016/S0140-6736(17)32812-X. Access: abstract_metadata. Study: NCT02032433.

15. Brandt L, Jones JD, Martinez S et al. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug and alcohol dependence. 2020. [PMID 31980285](https://pubmed.ncbi.nlm.nih.gov/31980285/). DOI: 10.1016/j.drugalcdep.2020.107859. Access: abstract_metadata. Study: PMID31980285.

16. Fudala PJ, Yu E, Macfadden W et al. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug and alcohol dependence. 1998. [PMID 9589267](https://pubmed.ncbi.nlm.nih.gov/9589267/). DOI: 10.1016/s0376-8716(98)00008-8. Access: abstract_metadata. Study: PMID9589267.

17. Higgins ST, Sigmon SC, Tidey JW et al. Reduced Nicotine Cigarettes and E-Cigarettes in High-Risk Populations: 3 Randomized Clinical Trials. JAMA network open. 2024. [PMID 39240566](https://pubmed.ncbi.nlm.nih.gov/39240566/). DOI: 10.1001/jamanetworkopen.2024.31731. Access: abstract_metadata. Study: NCT04090879+NCT04092101+NCT04092387.

18. Lofwall MR, Walsh SL, Nunes EV et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA internal medicine. 2018. [PMID 29799968](https://pubmed.ncbi.nlm.nih.gov/29799968/). DOI: 10.1001/jamainternmed.2018.1052. Access: abstract_metadata. Study: NCT02651584.

19. Robinson AH, Perales JC, Volpe I et al. Are methamphetamine users compulsive? Faulty reinforcement learning, not inflexibility, underlies decision making in people with methamphetamine use disorder. Addiction biology. 2021. [PMID 33393187](https://pubmed.ncbi.nlm.nih.gov/33393187/). DOI: 10.1111/adb.12999. Access: abstract_metadata. Study: PMID33393187.

20. Vandaele Y, Augier E, Vouillac-Mendoza C et al. Cocaine falls into oblivion during volitional initiation of choice trials. Addiction biology. 2022. [PMID 36301214](https://pubmed.ncbi.nlm.nih.gov/36301214/). DOI: 10.1111/adb.13235. Access: abstract_metadata. Study: PMID36301214.

21. Augier E, Barbier E, Dulman RS et al. A molecular mechanism for choosing alcohol over an alternative reward. Science (New York, N.Y.). 2018. [PMID 29930131](https://pubmed.ncbi.nlm.nih.gov/29930131/). DOI: 10.1126/science.aao1157. Access: abstract_metadata. Study: PMID29930131.

22. Hendershot CS, Bremmer MP, Paladino MB et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA psychiatry. 2025. [PMID 39937469](https://pubmed.ncbi.nlm.nih.gov/39937469/). DOI: 10.1001/jamapsychiatry.2024.4789. Access: abstract_metadata. Study: NCT05520775.

23. Schacht JP, Sakai JT, Raymond K et al. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. The American journal of psychiatry. 2026. [PMID 42522065](https://pubmed.ncbi.nlm.nih.gov/42522065/). DOI: 10.1176/appi.ajp.20260003. Access: abstract_metadata. Study: PMID42522065.

24. Klausen MK, Justesen SK, Pedersen JN et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2026. [PMID 42070571](https://pubmed.ncbi.nlm.nih.gov/42070571/). DOI: 10.1016/S0140-6736(26)00305-3. Access: abstract_metadata. Study: NCT05895643.

25. Wang W, Volkow ND, Berger NA et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular psychiatry. 2024. [PMID 38486046](https://pubmed.ncbi.nlm.nih.gov/38486046/). DOI: 10.1038/s41380-024-02498-5. Access: abstract_metadata. Study: PMID38486046.

26. Fink-Jensen A, Wörtwein G, Klausen MK et al. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology. 2025. [PMID 38884652](https://pubmed.ncbi.nlm.nih.gov/38884652/). DOI: 10.1007/s00213-024-06637-2. Access: abstract_metadata. Study: PMID38884652.

27. Halladay LR, Kocharian A, Piantadosi PT et al. Prefrontal Regulation of Punished Ethanol Self-administration. Biological psychiatry. 2020. [PMID 31937415](https://pubmed.ncbi.nlm.nih.gov/31937415/). DOI: 10.1016/j.biopsych.2019.10.030. Access: abstract_metadata. Study: PMID31937415.

28. Ducret E, Puaud M, Lacoste J et al. N-acetylcysteine Facilitates Self-Imposed Abstinence After Escalation of Cocaine Intake. Biological psychiatry. 2016. [PMID 26592462](https://pubmed.ncbi.nlm.nih.gov/26592462/). DOI: 10.1016/j.biopsych.2015.09.019. Access: abstract_metadata. Study: PMID26592462.

29. Pascoli V, Hiver A, Li Y et al. Cell-type specific synaptic plasticity in dorsal striatum is associated with punishment-resistance compulsive-like cocaine self-administration in mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023. [PMID 36071131](https://pubmed.ncbi.nlm.nih.gov/36071131/). DOI: 10.1038/s41386-022-01429-8. Access: abstract_metadata. Study: PMID36071131.

30. Duan Y, Tsai PJ, Salmeron BJ et al. Compulsive drug-taking is associated with habenula-frontal cortex connectivity. Proceedings of the National Academy of Sciences of the United States of America. 2022. [PMID 36469769](https://pubmed.ncbi.nlm.nih.gov/36469769/). DOI: 10.1073/pnas.2208867119. Access: abstract_metadata. Study: PMID36469769.

31. Farrell MR, Ruiz CM, Castillo E et al. Ventral pallidum is essential for cocaine relapse after voluntary abstinence in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2019. [PMID 31476762](https://pubmed.ncbi.nlm.nih.gov/31476762/). DOI: 10.1038/s41386-019-0507-4. Access: abstract_metadata. Study: PMID31476762.

32. Terraneo A, Leggio L, Saladini M et al. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2016. [PMID 26655188](https://pubmed.ncbi.nlm.nih.gov/26655188/). DOI: 10.1016/j.euroneuro.2015.11.011. Access: abstract_metadata. Study: PMID26655188.

33. Pascoli V, Terrier J, Hiver A et al. Sufficiency of Mesolimbic Dopamine Neuron Stimulation for the Progression to Addiction. Neuron. 2015. [PMID 26586182](https://pubmed.ncbi.nlm.nih.gov/26586182/). DOI: 10.1016/j.neuron.2015.10.017. Access: abstract_metadata. Study: PMID26586182.

34. Torres OV, Jayanthi S, Ladenheim B et al. Compulsive methamphetamine taking under punishment is associated with greater cue-induced drug seeking in rats. Behavioural brain research. 2017. [PMID 28284948](https://pubmed.ncbi.nlm.nih.gov/28284948/). DOI: 10.1016/j.bbr.2017.03.009. Access: abstract_metadata. Study: PMID28284948.

35. Corre J, van Zessen R, Loureiro M et al. Dopamine neurons projecting to medial shell of the nucleus accumbens drive heroin reinforcement. eLife. 2018. [PMID 30373717](https://pubmed.ncbi.nlm.nih.gov/30373717/). DOI: 10.7554/eLife.39945. Access: abstract_metadata. Study: PMID30373717.

36. Fouyssac M, Hynes T, Belin-Rauscent A et al. Incentive Cocaine-Seeking Habits and Their Compulsive Manifestation Emerge After a Downregulation of the Dopamine Transporter in Astrocytes Across Functional Domains of the Striatum. The European journal of neuroscience. 2025. [PMID 40082733](https://pubmed.ncbi.nlm.nih.gov/40082733/). DOI: 10.1111/ejn.70054. Access: abstract_metadata. Study: PMID40082733.

37. Harada M, Pascoli V, Hiver A et al. Corticostriatal Activity Driving Compulsive Reward Seeking. Biological psychiatry. 2021. [PMID 34688471](https://pubmed.ncbi.nlm.nih.gov/34688471/). DOI: 10.1016/j.biopsych.2021.08.018. Access: abstract_metadata. Study: PMID34688471.

38. Domi E, Xu L, Toivainen S et al. A neural substrate of compulsive alcohol use. Science advances. 2021. [PMID 34407947](https://pubmed.ncbi.nlm.nih.gov/34407947/). DOI: 10.1126/sciadv.abg9045. Access: full_text_partial. Study: PMID34407947.

39. Lepack AE, Werner CT, Stewart AF et al. Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking. Science (New York, N.Y.). 2020. [PMID 32273471](https://pubmed.ncbi.nlm.nih.gov/32273471/). DOI: 10.1126/science.aaw8806. Access: abstract_metadata. Study: PMID32273471.

40. Lenoir M, Cantin L, Vanhille N et al. Extended heroin access increases heroin choices over a potent nondrug alternative. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2013. [PMID 23322185](https://pubmed.ncbi.nlm.nih.gov/23322185/). DOI: 10.1038/npp.2013.17. Access: abstract_metadata. Study: PMID23322185.

41. Wang ZJ, Martin JA, Mueller LE et al. BRG1 in the Nucleus Accumbens Regulates Cocaine-Seeking Behavior. Biological psychiatry. 2016. [PMID 27422367](https://pubmed.ncbi.nlm.nih.gov/27422367/). DOI: 10.1016/j.biopsych.2016.04.020. Access: abstract_metadata. Study: PMID27422367.

42. Christian DT, Stefanik MT, Bean LA et al. GluN3-Containing NMDA Receptors in the Rat Nucleus Accumbens Core Contribute to Incubation of Cocaine Craving. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2021. [PMID 34413203](https://pubmed.ncbi.nlm.nih.gov/34413203/). DOI: 10.1523/JNEUROSCI.0406-21.2021. Access: abstract_metadata. Study: PMID34413203.

43. Saddoris MP, Carelli RM. Cocaine self-administration abolishes associative neural encoding in the nucleus accumbens necessary for higher-order learning. Biological psychiatry. 2014. [PMID 24035479](https://pubmed.ncbi.nlm.nih.gov/24035479/). DOI: 10.1016/j.biopsych.2013.07.037. Access: abstract_metadata. Study: PMID24035479.

44. Sun W, Akins CK, Mattingly AE et al. Ionotropic glutamate receptors in the ventral tegmental area regulate cocaine-seeking behavior in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005. [PMID 15841101](https://pubmed.ncbi.nlm.nih.gov/15841101/). DOI: 10.1038/sj.npp.1300744. Access: abstract_metadata. Study: PMID15841101.

45. Durazzo TC, Pennington DL, Schmidt TP et al. Effects of cigarette smoking history on neurocognitive recovery over 8 months of abstinence in alcohol-dependent individuals. Alcoholism, clinical and experimental research. 2014. [PMID 25336410](https://pubmed.ncbi.nlm.nih.gov/25336410/). DOI: 10.1111/acer.12552. Access: abstract_metadata. Study: PMID25336410.

46. Leung PK, Kinzie JD, Boehnlein JK et al. A prospective study of the natural course of alcoholism in a Native American village. Journal of studies on alcohol. 1993. [PMID 8271810](https://pubmed.ncbi.nlm.nih.gov/8271810/). DOI: 10.15288/jsa.1993.54.733. Access: abstract_metadata. Study: PMID8271810.

47. Petit G, Luminet O, Cordovil de Sousa Uva M et al. Differential spontaneous recovery across cognitive abilities during detoxification period in alcohol-dependence. PloS one. 2017. [PMID 28767647](https://pubmed.ncbi.nlm.nih.gov/28767647/). DOI: 10.1371/journal.pone.0176638. Access: abstract_metadata. Study: PMID28767647.

48. Bach P, Koopmann A, Bumb JM et al. Leptin predicts cortical and subcortical gray matter volume recovery in alcohol dependent patients: A longitudinal structural magnetic resonance imaging study. Hormones and behavior. 2020. [PMID 32387173](https://pubmed.ncbi.nlm.nih.gov/32387173/). DOI: 10.1016/j.yhbeh.2020.104749. Access: abstract_metadata. Study: PMID32387173.

49. Vaillant GE. A 60-year follow-up of alcoholic men. Addiction (Abingdon, England). 2003. [PMID 12873238](https://pubmed.ncbi.nlm.nih.gov/12873238/). DOI: 10.1046/j.1360-0443.2003.00422.x. Access: abstract_metadata. Study: PMID12873238.

50. Tucker JA, Cheong J, James TG et al. Preresolution Drinking Problem Severity Profiles Associated with Stable Moderation Outcomes of Natural Recovery Attempts. Alcoholism, clinical and experimental research. 2020. [PMID 31984515](https://pubmed.ncbi.nlm.nih.gov/31984515/). DOI: 10.1111/acer.14287. Access: abstract_metadata. Study: PMID31984515.

51. Sigmon SC, Miller ME, Meyer AC et al. Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial. Addiction (Abingdon, England). 2016. [PMID 26638126](https://pubmed.ncbi.nlm.nih.gov/26638126/). DOI: 10.1111/add.13264. Access: abstract_metadata. Study: PMID26638126.

52. Shoptaw S, Heinzerling KG, Rotheram-Fuller E et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and alcohol dependence. 2008. [PMID 18468815](https://pubmed.ncbi.nlm.nih.gov/18468815/). DOI: 10.1016/j.drugalcdep.2008.03.010. Access: abstract_metadata. Study: PMID18468815.

53. Somoza EC, Winship D, Gorodetzky CW et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA psychiatry. 2013. [PMID 23575810](https://pubmed.ncbi.nlm.nih.gov/23575810/). DOI: 10.1001/jamapsychiatry.2013.872. Access: abstract_metadata. Study: NCT00611130.

54. Maricich YA, Bickel WK, Marsch LA et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Current medical research and opinion. 2021. [PMID 33140994](https://pubmed.ncbi.nlm.nih.gov/33140994/). DOI: 10.1080/03007995.2020.1846022. Access: abstract_metadata. Study: NCT00929253.

55. Schmitz JM, Stotts AL, Vujanovic AA et al. Contingency management plus acceptance and commitment therapy for initial cocaine abstinence: Results of a sequential multiple assignment randomized trial (SMART). Drug and alcohol dependence. 2024. [PMID 38309089](https://pubmed.ncbi.nlm.nih.gov/38309089/). DOI: 10.1016/j.drugalcdep.2023.111078. Access: abstract_metadata. Study: PMID38309089.

56. Miguel AQ, Madruga CS, Cogo-Moreira H et al. Contingency management is effective in promoting abstinence and retention in treatment among crack cocaine users in Brazil: A randomized controlled trial. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2016. [PMID 27442691](https://pubmed.ncbi.nlm.nih.gov/27442691/). DOI: 10.1037/adb0000192. Access: full_text_partial. Study: PMID27442691.

## Source-specific evidence cards

### [1] A randomized trial of contingency management for adolescent marijuana abuse and dependence.

**Shows:** Randomized adolescent contingency management improved marijuana abstinence during treatment.

**Does not show:** Parent training and multiple treatment components do not isolate a neural mediator or establish permanent remission.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [2] Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.

**Shows:** Dexamfetamine reduced cocaine-use days in refractory cocaine dependence with heroin-assisted treatment.

**Does not show:** Selected comorbidity, adverse effects and agonist substitution do not establish a universal loss-of-volition mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [3] Individual characteristics and response to Contingency Management treatment for cocaine addiction.

**Shows:** Baseline alcohol problems and early abstinence predicted response to contingency management.

**Does not show:** A treated cohort's predictors are not randomized mediator manipulation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [4] Enhancing patient navigation with contingent financial incentives for substance use abatement in persons with HIV and substance use.

**Shows:** Incentives added to patient navigation increased substance-treatment entry and negative sample submission in HIV.

**Does not show:** Multiple components and unequal submission rates complicate interpretation; no selective neural-mediator assay.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [5] A randomized study of cellphone technology to reinforce alcohol abstinence in the natural environment.

**Shows:** Cellphone-linked contingency management improved alcohol-negative breath measures and selected drinking outcomes.

**Does not show:** Behavioral response does not imply no brain changes; sample submission and setting restrict scope.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [6] Remission from substance dependence: differences between individuals in a general population longitudinal survey who do and do not seek help.

**Shows:** Population follow-up found substantial remission, differing between help-seeking and non-help-seeking groups.

**Does not show:** Severity selection prevents concluding treatment harms recovery or all disorders remit easily.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [7] Functional Connectivity of Chronic Cocaine Use Reveals Progressive Neuroadaptations in Neocortical, Striatal, and Limbic Networks.

**Shows:** Longitudinal rats showed transient connectivity-topology changes after cocaine or sucrose exposure.

**Does not show:** Shared reward effects and recovery restrict claims of irreversible drug-specific pathology.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [8] Dissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum.

**Shows:** Methylphenidate altered impulsivity and receptor availability without a clear relationship between their changes.

**Does not show:** The candidate dopamine imaging mediator was not established as the causal bridge.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [9] Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study.

**Shows:** Baclofen changed resting cerebral blood flow in reward-related regions.

**Does not show:** Acute imaging change without smoking reduction is not symptom-trajectory causality.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [10] Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men.

**Shows:** Repeated laboratory stimulant exposure produced persistent dopamine-release sensitization in healthy men.

**Does not show:** Sensitization is not diagnosed addiction, human loss of agency or general relapse inevitability.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [11] In Vivo Observation of Structural Changes in Neocortical Catecholaminergic Projections in Response to Drugs of Abuse.

**Shows:** Mouse imaging found transient catecholaminergic bouton-volume responses to methamphetamine.

**Does not show:** Structural pharmacodynamic responses do not establish chronic human compulsivity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [12] Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers.

**Shows:** Smoking abstinence was associated with recovery of dopamine-synthesis measures.

**Does not show:** Nonrandomized abstinence and proxy measures do not establish that the change causes remission.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [13] Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.

**Shows:** A randomized buprenorphine-formulation trial found similar treatment engagement, with selected secondary differences.

**Does not show:** Two active formulations do not isolate neural necessity; an erratum is attached.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID41915466. Subclaims: SC2, SC3.

### [14] Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

**Shows:** X:BOT found an induction hurdle for naltrexone explaining much intention-to-treat relapse difference versus buprenorphine.

**Does not show:** Per-protocol similarity conditions on successful induction; neither result proves unified loss of volition.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [15] Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.

**Shows:** Lorcaserin did not reduce oxycodone self-administration under tested conditions.

**Does not show:** A specific negative pharmacological test does not invalidate every neural adaptation mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [16] Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

**Shows:** An opioid challenge produced withdrawal responses in morphine-stabilized dependent participants.

**Does not show:** Physiological dependence is not equivalent to addiction, compulsive choice or universal chronic relapse.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [17] Reduced Nicotine Cigarettes and E-Cigarettes in High-Risk Populations: 3 Randomized Clinical Trials.

**Shows:** Reduced-nicotine cigarettes and preferred-flavor alternatives decreased smoking in randomized high-risk groups.

**Does not show:** Nicotine exposure and alternative rewards both change; a broad neural-primacy claim is not isolated.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [18] Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

**Shows:** Depot buprenorphine was noninferior on prespecified outcomes and favored the distribution of illicit-use outcomes.

**Does not show:** Active-formulation comparison supports treatment effects, not a universally necessary brain lesion.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [19] Are methamphetamine users compulsive? Faulty reinforcement learning, not inflexibility, underlies decision making in people with methamphetamine use disorder.

**Shows:** Methamphetamine-use-disorder participants showed weaker reinforcement learning without greater task inflexibility.

**Does not show:** Small task-based observational differences do not establish all real-world compulsivity or its absence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [20] Cocaine falls into oblivion during volitional initiation of choice trials.

**Shows:** Most rats preferred a sweet alternative to cocaine even when controlling trial initiation.

**Does not show:** Laboratory alternatives and species scope do not make severe human addiction trivial.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [21] A molecular mechanism for choosing alcohol over an alternative reward.

**Shows:** Amygdala GAT-3 knockdown shifted rats toward alcohol choice, with related human postmortem expression findings.

**Does not show:** Rat choice causality plus human association do not establish human mediator necessity or universal loss of agency.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [22] Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.

**Shows:** A small semaglutide AUD trial reduced laboratory consumption and selected drinking/craving endpoints.

**Does not show:** Drinks per calendar day and drinking days did not change; nonspecific intake/weight effects and small sample limit mechanism attribution.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [23] Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.

**Shows:** Oral semaglutide reduced selected heavy-drinking and naturalistic outcomes in AUD.

**Does not show:** Laboratory craving and drinks-per-day endpoints were not significant; drug benefit does not prove the nominal universal mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [24] Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.

**Shows:** Semaglutide reduced heavy-drinking days versus placebo in AUD with obesity.

**Does not show:** Obesity scope and subjective/physiological drug effects restrict mechanistic specificity and generalization.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [25] Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.

**Shows:** Matched EHR cohorts associated semaglutide with fewer cannabis-use-disorder diagnoses.

**Does not show:** Confounding, coding and treatment selection remain; not a randomized addiction-mechanism intervention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [26] Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.

**Shows:** Semaglutide reduced voluntary alcohol consumption in male vervet monkeys.

**Does not show:** Nonhuman voluntary consumption is not a human functional loss-of-control endpoint.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [27] Prefrontal Regulation of Punished Ethanol Self-administration.

**Shows:** Closed-loop prefrontal inhibition altered punishment-related ethanol seeking in rats.

**Does not show:** Model circuit specificity does not prove broad human symptom-trajectory causality.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [28] N-acetylcysteine Facilitates Self-Imposed Abstinence After Escalation of Cocaine Intake.

**Shows:** N-acetylcysteine promoted punishment-linked abstinence in long-access cocaine rats and altered glutamate transport measures.

**Does not show:** Drug pleiotropy and associated molecular recovery do not isolate every causal mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [29] Cell-type specific synaptic plasticity in dorsal striatum is associated with punishment-resistance compulsive-like cocaine self-administration in mice.

**Shows:** Mouse striatal synaptic changes tracked progression to punishment-resistant cocaine self-administration.

**Does not show:** Association/timing do not alone establish that the adaptation is necessary in humans.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [30] Compulsive drug-taking is associated with habenula-frontal cortex connectivity.

**Shows:** Longitudinal rat habenula-frontal connectivity related to punishment-resistant methamphetamine taking.

**Does not show:** Imaging correlation is not mediator manipulation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [31] Ventral pallidum is essential for cocaine relapse after voluntary abstinence in rats.

**Shows:** Ventral-pallidum inhibition reduced cocaine relapse-like behavior after voluntary abstinence in rats.

**Does not show:** Model relapse and possible risk-assessment effects cannot establish universal human chronicity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [32] Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study.

**Shows:** A small randomized open-control TMS study improved cocaine urine/craving outcomes.

**Does not show:** No matched sham or adequate blinding establishes an expectancy-independent neural mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [33] Sufficiency of Mesolimbic Dopamine Neuron Stimulation for the Progression to Addiction.

**Shows:** Optogenetic dopamine stimulation produced reinforcement and selected relapse/compulsion-like behaviors in mice.

**Does not show:** Artificial stimulation sufficiency for a model phenotype is not endogenous necessity or universal human loss of volition.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [34] Compulsive methamphetamine taking under punishment is associated with greater cue-induced drug seeking in rats.

**Shows:** Punishment-resistant methamphetamine rats showed greater later cue-induced seeking.

**Does not show:** Selection by behavior and rodent proxy outcomes do not establish general human compulsivity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [35] Dopamine neurons projecting to medial shell of the nucleus accumbens drive heroin reinforcement.

**Shows:** Targeted dopamine-neuron manipulations altered heroin reinforcement in mice.

**Does not show:** Reinforcement is not identical to chronic compulsivity, and species/perturbation scope matters.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [36] Incentive Cocaine-Seeking Habits and Their Compulsive Manifestation Emerge After a Downregulation of the Dopamine Transporter in Astrocytes Across Functional Domains of the Striatum.

**Shows:** Cocaine habit phenotypes associated with reduced astrocytic dopamine-transporter expression in rats.

**Does not show:** Expression changes without a selective restoration test do not establish necessity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [37] Corticostriatal Activity Driving Compulsive Reward Seeking.

**Shows:** Corticostriatal inhibition reduced punished reward seeking in mice.

**Does not show:** Reward-proxy circuit effects do not establish human diagnostic specificity or universal agency loss.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [38] A neural substrate of compulsive alcohol use.

**Shows:** Targeted amygdala ensemble inhibition and PKC-delta knockdown reduced punishment-resistant alcohol taking in rats.

**Does not show:** Phenotype-selected animals and rodent punishment tasks do not establish a generally primary mechanism in humans.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:RESULTS:paragraph12, 1:RESULTS:paragraph19, 1:RESULTS:paragraph21. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [39] Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking.

**Shows:** Reducing VTA histone dopaminylation changed gene expression/dopamine release and cocaine seeking in rats.

**Does not show:** A specific model relapse pathway is not a universal human brain-disease mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [40] Extended heroin access increases heroin choices over a potent nondrug alternative.

**Shows:** Extended heroin access increased drug preference relative to a nondrug alternative in rats.

**Does not show:** Drug-specific susceptibility and alternatives constrain generalization across substances and people.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [41] BRG1 in the Nucleus Accumbens Regulates Cocaine-Seeking Behavior.

**Shows:** Accumbens BRG1 inhibition and overexpression oppositely altered cocaine reinstatement in rats.

**Does not show:** Local model manipulation does not establish human necessity or the etiology of every substance disorder.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [42] GluN3-Containing NMDA Receptors in the Rat Nucleus Accumbens Core Contribute to Incubation of Cocaine Craving.

**Shows:** GluN3A knockdown prevented incubation of cue-induced cocaine craving in rats.

**Does not show:** Cue seeking is a model phenotype, not direct human relapse or generalized volitional incapacity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [43] Cocaine self-administration abolishes associative neural encoding in the nucleus accumbens necessary for higher-order learning.

**Shows:** Cocaine-experienced rats showed impaired higher-order learning and altered accumbens encoding.

**Does not show:** Drug exposure can cause impairment but this does not demonstrate universal human addiction maintenance.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [44] Ionotropic glutamate receptors in the ventral tegmental area regulate cocaine-seeking behavior in rats.

**Shows:** VTA glutamate blockade reduced cocaine reinstatement with location and sucrose controls.

**Does not show:** Specific model reinstatement effects do not establish a human syndrome-wide causal driver.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [45] Effects of cigarette smoking history on neurocognitive recovery over 8 months of abstinence in alcohol-dependent individuals.

**Shows:** Alcohol abstinence was associated with cognitive improvement varying by smoking status.

**Does not show:** Recovery and smoking confounding do not establish either permanent damage or its complete absence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [46] A prospective study of the natural course of alcoholism in a Native American village.

**Shows:** Long village follow-up documented substantial spontaneous alcohol remission with sex differences.

**Does not show:** Historical community setting and observational severity selection preclude universal remission estimates.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [47] Differential spontaneous recovery across cognitive abilities during detoxification period in alcohol-dependence.

**Shows:** Detoxification follow-up showed recovery in working memory with persistent selected inhibition deficits.

**Does not show:** Short time course and individual heterogeneity do not establish all functions recover or remain impaired.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [48] Leptin predicts cortical and subcortical gray matter volume recovery in alcohol dependent patients: A longitudinal structural magnetic resonance imaging study.

**Shows:** Longitudinal MRI showed partial brain-volume recovery associated with leptin during alcohol abstinence.

**Does not show:** Correlated recovery and hormone levels do not establish a manipulated causal mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [49] A 60-year follow-up of alcoholic men.

**Shows:** Long male-cohort follow-up found both stable abstinence and substantial mortality, with dependence predicting course.

**Does not show:** Survivor bias and sex/historical scope prevent equating low late-life dependence prevalence with easy remission.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [50] Preresolution Drinking Problem Severity Profiles Associated with Stable Moderation Outcomes of Natural Recovery Attempts.

**Shows:** Natural-recovery profiles predicted moderation, abstinence and relapse differently by severity.

**Does not show:** Observational profile prediction is not a causal treatment or mechanism test.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [51] Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial.

**Shows:** Contingent incentives improved verified smoking abstinence in opioid-maintained patients.

**Does not show:** Some duration measures were nonsignificant; reinforcement responsiveness does not imply brain-independent choice.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [52] Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.

**Shows:** Bupropion did not improve planned methamphetamine-use outcomes, with a post hoc light-use subgroup signal.

**Does not show:** Exploratory subgroup benefit cannot replace the primary null or invalidate all pharmacological treatment.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [53] A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

**Shows:** A multisite vigabatrin trial found no protocol-defined cocaine efficacy difference.

**Does not show:** Possible medication nonadherence prevents treating the null as verified target failure.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [54] Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.

**Shows:** A digital therapeutic added to buprenorphine improved opioid abstinence and retention.

**Does not show:** Combined behavioral/pharmacological treatment does not identify one required neural lesion.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [55] Contingency management plus acceptance and commitment therapy for initial cocaine abstinence: Results of a sequential multiple assignment randomized trial (SMART).

**Shows:** A sequential randomized study supported selected ACT-plus-contingency-management response findings but not modafinil augmentation.

**Does not show:** Adaptive design and probabilistic evidence do not isolate a universal mediator or guarantee sustained remission.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [56] Contingency management is effective in promoting abstinence and retention in treatment among crack cocaine users in Brazil: A randomized controlled trial.

**Shows:** Randomized contingency management improved retention and sustained crack-cocaine-negative runs.

**Does not show:** Negative-sample proportions differed using expected samples but not submitted samples, making engagement part of the result; no neural-state measurement.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph3, 2:Results:paragraph5. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.